Objective:

To evaluate the effectiveness of individualized beta-lactam dosing guided by measured drug levels in critically ill patients.

Approach:

• Panel Composition: A 19-member international panel of experts in various fields convened to develop recommendations.
• Evidence Review: The panel conducted a systematic review of research databases and clinical trial registries, screening studies and extracting data.
• Consensus Development: When evidence was insufficient, expert consensus was used to develop best-practice statements.

Key Findings:

• Patients receiving individualized beta-lactam dosing had nearly twice the odds of clinical cure compared to usual care.
• The evidence for mortality reduction was inconclusive, with no statistically significant difference found.
• Individualized dosing did not significantly improve microbiologic eradication or shorten hospital stays.

Interpretation:

The panel conditionally recommended individualized dosing for critically ill patients and those with altered kidney function.

Limitations:

• Few randomized trials and differences in outcome definitions.
• Uncertainty in results and limited access to rapid drug-level testing.
• Safety evidence remains unclear, particularly regarding high beta-lactam levels.

Conclusion:

Individualized beta-lactam dosing may improve treatment outcomes.

Sources:

• Pharmacotherapy